Profil
Timothy Kieffer is Chief Scientific Officer at Aardvark Therapeutics, Inc. since 2025.
Formerly, Dr. Kieffer was Chief Scientific Officer at Fractyl Health, Inc., Chief Scientific Officer at ViaCyte, Inc. from 2021 to 2022, and Professor at the University of British Columbia.
Dr. Kieffer earned a doctorate from the University of British Columbia.
Aktive Positionen von Timothy Kieffer
| Unternehmen | Position | Beginn |
|---|---|---|
| AARDVARK THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 20.05.2025 |
Ehemalige bekannte Positionen von Timothy Kieffer
| Unternehmen | Position | Ende |
|---|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative medicines for people with serious diseases | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2022 |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| FRACTYL HEALTH, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Timothy Kieffer
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative medicines for people with serious diseases | Health Technology |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fractyl Health, Inc.
Fractyl Health, Inc. BiotechnologyHealth Technology Develops and sells therapeutics for metabolic diseases, type 2 diabetes & obesity | Health Technology |
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics for obesity and metabolic diseases | Health Technology |
















